JPWO2019200033A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019200033A5
JPWO2019200033A5 JP2020556258A JP2020556258A JPWO2019200033A5 JP WO2019200033 A5 JPWO2019200033 A5 JP WO2019200033A5 JP 2020556258 A JP2020556258 A JP 2020556258A JP 2020556258 A JP2020556258 A JP 2020556258A JP WO2019200033 A5 JPWO2019200033 A5 JP WO2019200033A5
Authority
JP
Japan
Prior art keywords
fusion protein
recombinant fusion
recombinant
nrg
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020556258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535727A (ja
JP2021535727A5 (https=
JP7575272B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026889 external-priority patent/WO2019200033A1/en
Publication of JP2021535727A publication Critical patent/JP2021535727A/ja
Publication of JPWO2019200033A5 publication Critical patent/JPWO2019200033A5/ja
Publication of JP2021535727A5 publication Critical patent/JP2021535727A5/ja
Priority to JP2023097663A priority Critical patent/JP7631420B2/ja
Application granted granted Critical
Publication of JP7575272B2 publication Critical patent/JP7575272B2/ja
Priority to JP2025017265A priority patent/JP2025072502A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020556258A 2018-04-11 2019-04-11 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法 Active JP7575272B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023097663A JP7631420B2 (ja) 2018-04-11 2023-06-14 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法
JP2025017265A JP2025072502A (ja) 2018-04-11 2025-02-05 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656246P 2018-04-11 2018-04-11
US62/656,246 2018-04-11
PCT/US2019/026889 WO2019200033A1 (en) 2018-04-11 2019-04-11 Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097663A Division JP7631420B2 (ja) 2018-04-11 2023-06-14 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法

Publications (4)

Publication Number Publication Date
JP2021535727A JP2021535727A (ja) 2021-12-23
JPWO2019200033A5 true JPWO2019200033A5 (https=) 2022-04-19
JP2021535727A5 JP2021535727A5 (https=) 2022-04-19
JP7575272B2 JP7575272B2 (ja) 2024-10-29

Family

ID=66484143

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020556258A Active JP7575272B2 (ja) 2018-04-11 2019-04-11 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法
JP2023097663A Active JP7631420B2 (ja) 2018-04-11 2023-06-14 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法
JP2025017265A Pending JP2025072502A (ja) 2018-04-11 2025-02-05 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023097663A Active JP7631420B2 (ja) 2018-04-11 2023-06-14 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法
JP2025017265A Pending JP2025072502A (ja) 2018-04-11 2025-02-05 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法

Country Status (25)

Country Link
US (3) US11046741B2 (https=)
EP (2) EP3774859B1 (https=)
JP (3) JP7575272B2 (https=)
KR (1) KR102949228B1 (https=)
CN (2) CN113166218B (https=)
AU (2) AU2019252262B2 (https=)
BR (1) BR112020020646A2 (https=)
CA (1) CA3096420A1 (https=)
CL (1) CL2020002621A1 (https=)
CO (1) CO2020012621A2 (https=)
DK (1) DK3774859T3 (https=)
EA (1) EA202092458A1 (https=)
ES (1) ES2980163T3 (https=)
FI (1) FI3774859T3 (https=)
HU (1) HUE066892T2 (https=)
IL (2) IL322374A (https=)
MX (2) MX2020010740A (https=)
MY (1) MY204230A (https=)
PE (1) PE20210111A1 (https=)
PH (1) PH12020551648A1 (https=)
PL (1) PL3774859T3 (https=)
PT (1) PT3774859T (https=)
SG (1) SG11202009831UA (https=)
TW (2) TWI888027B (https=)
WO (1) WO2019200033A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210111A1 (es) 2018-04-11 2021-01-19 Salubris Biotherapeutics Inc Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
AU2020348436A1 (en) * 2019-09-16 2022-04-07 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
CN114420310B (zh) * 2022-01-18 2024-11-12 河南大学 基于图转换网络的药物ATC Code预测方法
WO2023178086A1 (en) * 2022-03-15 2023-09-21 Salubris Biotherapeutics, Inc. Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein
CN116832040B (zh) * 2023-06-12 2026-01-13 北京市心肺血管疾病研究所 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
WO2025122581A1 (en) * 2023-12-08 2025-06-12 The Trustees Of Indiana University Compositions comprising neuregulin and methods of using the same to treat or prevent neurotrophic keratitis
WO2025245112A1 (en) 2024-05-21 2025-11-27 Salubris Biotherapeutics, Inc. Neuregulin-1/anti-her3 antibody fusion protein for use in the treatment of heart failure

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP1824879B1 (en) 2004-07-09 2014-10-29 Wayne State University HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
BRPI0818033A2 (pt) 2007-10-16 2015-03-24 Symphogen As Composições compreendendo multímeros otimizados de her1 e her3 e métodos para usos dos mesmos
WO2009114110A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
WO2010006059A1 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
JP2013507378A (ja) * 2009-10-09 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション 抗her3抗体の製造、特徴づけ及びその用途
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
CA2929386C (en) * 2013-11-07 2023-01-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-her3 antibody
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
KR102399277B1 (ko) * 2014-04-10 2022-05-18 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
CA2959716A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
RU2767329C2 (ru) 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
CN110167968B (zh) 2016-09-15 2023-11-28 斯图加特大学 针对her3的抗原结合蛋白
PE20210111A1 (es) 2018-04-11 2021-01-19 Salubris Biotherapeutics Inc Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso

Similar Documents

Publication Publication Date Title
JP2021535727A5 (https=)
FI3774859T3 (fi) Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät
AU2020201323B2 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
JP7358365B2 (ja) がんを治療するための、化学療法剤と併用した多量体抗dr5結合分子の使用
CN107074928B (zh) 新型猫促红细胞生成素受体激动剂
KR101201339B1 (ko) 인간 epo 미메틱 힌지 코어 미메티바디, 조성물, 방법및 용도
Baldwin Comparison of transferrin sequences from different species
JP4398644B2 (ja) ErbB界面ペプチド擬態およびその使用方法
KR20050033563A (ko) 포유동물 epo 모방 ch1 결실된 모방체, 조성물, 방법및 용도
CN107446045A (zh) 一种抗her2的抗体、其药物组合物及用途
US20090318346A1 (en) BIVALENT ErbB LIGAND BINDING MOLECULES AND METHODS FOR THEIR PREPARATION AND USE
AU2009213141A1 (en) Targeted therapeutics based on engineered proteins that bind EGFR
US9731007B2 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
KR20230010221A (ko) 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도
JPWO2019200033A5 (https=)
EP3833690B1 (en) Recombinant bifunctional protein targeting cd47 and her2
KR20150097304A (ko) 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
WO2022242757A1 (zh) 抗pd-1抗体的应用
US20230279144A1 (en) Anti-her2 antibody and use thereof
JP7829127B2 (ja) 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質
KR20140025836A (ko) 항 HER2/Neu 단일클론항체와 IL-7가 연결된 융합 단일클론 항체 및 이를 포함하는 암 치료용 조성물
US20090148440A1 (en) Antibodies against interleukin-22 binding protein and its uses for the treatment of metabolic disorders
CN110536902A (zh) 蛋白质的纯度及对于抗原的亲和性得到提高的多肽、与其抗体或抗原结合片段间的复合物及它们的制备方法
TW202342551A (zh) 包含抗原結合結構域及細胞因數三聚體結構域的融合蛋白
JPWO2021133167A5 (https=)